DOCSLIB.ORG

Neuromodulation for Treatment-Refractory Major Depressive Disorder

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neuromodulation for Treatment-Refractory Major Depressive Disorder CMAJ Review CME Neuromodulation for treatment-refractory major depressive disorder Nir Lipsman MD, Tejas Sankar MD, Jonathan Downar MD PhD, Sidney H. Kennedy MD, Andres M. Lozano MD PhD, Peter Giacobbe MD MSc ajor depressive disorder is among the cranial direct current stimulation.6 Invasive Competing interests: See most prevalent psychiatric disorders options include vagal nerve stimulation7 and deep end of article. and is a leading cause of morbidity brain stimulation. Here we focus on the 3 modali- This article has been peer M 1 and lost productivity. The 1-year prevalence of ties for which the most evidence is currently reviewed. major depressive disorder in the Canadian popu- available: electroconvulsive therapy, transcranial Correspondence to: lation is 3.2%–4.6%.2 A large, multisite prospec- magnetic stimulation and deep brain stimulation. Peter Giacobbe, tive trial showed that only 28% of patients ex - [email protected] peri ence remission following monotherapy with Electroconvulsive therapy CMAJ 2014. DOI:10.1503 /cmaj.121317 a serotonin reuptake inhibitor.3 Further, remis- Electroconvulsive therapy is the oldest neuro- sion rates following antidepressant use decrease modulatory modality still used to treat major with each successive treatment failure, such that depressive disorder. It arguably remains the after 12 months of follow-up and up to 4 gold-standard to which other antidepressant attempts at symptom control with different med- treatments are compared, yet it is underused.8 ications, only 60% of patients experience remis- Electroconvulsive therapy involves the adminis- sion.4,5 The remaining patients can be classified tration of an electrical current to the brain via the as having treatment-refractory depression. scalp to induce a seizure while the patient is in a The failure of monoamine-modulating medi - state of general anesthesia. Although its mech an - cat ions to successfully treat a significant percent- isms are unknown,9 the superiority of real elec- age of cases of major depressive disorder chal- troconvulsive therapy over sham electroconvul- lenges the traditional conception of this sive therapy (anesthesia, with or without a condition as a monoamine deficiency state.5 subconvulsive dose of electrical current) sug- Accordingly, and in light of neurocircuitry mod- gests that the induction of the seizure plays a role els of the brain (Appendix 1, available at www in the antidepressant effects of this treatment.10,11 .cmaj .ca /lookup /suppl /doi :10 .1503 /cmaj .121317 / Meta-analyses comparing electroconvulsive -/DC1) and advances in technology allowing var- therapy to antidepressant medication (Table 1) ious means of modulating activity in key struc- have found that electroconvulsive therapy is sup - tures of the brain, interest in the therapeutic er ior to medication in reducing depressive symp- potential of neuromodulation for difficult-to-treat toms (effect size 0.80, 95% confidence interval mood disorders has increased in recent years. In [CI] 0.29–1.29)10 and in achieving an antidepres- this review, we outline the mechanisms, safety sant response, defined as a 50% or greater reduc- and clinical evidence for neuromodulation in tion in patients’ scores on the Hamilton Rating treatment-refractory major depression. The qual- scale for Depression compared with baseline ity of evidence for the different neuromodulation (odds ratio [OR] 3.72, 95% CI 2.60–5.32).11 Tra- strategies varies substantially, ranging from ditionally, it has been thought that the melan- small, open-label case series to blinded, random- ized controlled trials and meta-analyses (Box 1). Key points • Major depressive disorder is often refractory to standard What are the neuromodulation pharmacologic treatment but may respond well to neuromodulation. options for major depression? • Transcranial magnetic stimulation is least invasive but is less effective than electroconvulsive therapy or deep brain stimulation for treatment of major depression. Neuromodulation is either noninvasive or inva- • The acceptability and tolerability of electroconvulsive therapy is hampered sive, based on the extent to which the technology by adverse effects on episodic memory and other forms of cognition. interacts directly with the brain (Figure 1). Non- • Neuromodulation can lead to major long-term improvements in invasive options include electroconvulsive ther- depression ratings and quality of life. apy, transcranial magnetic stimulation and trans - © 2014 Canadian Medical Association or its licensors CMAJ, January 7, 2014, 186(1) 33 Review cholic subtype of major depressive disorder was convulsive Therapy suggest that the median num- the most responsive to electroconvulsive therapy, ber of electroconvulsive therapy treatments although recent studies have suggested that elec- required to produce an antidepressant response is troconvulsive therapy can produce an antidepres- 3, the number for resolution of suicidal thoughts sant response across multiple subtypes of major is 4, and the number for remission is 7.14 Given depressive episodes.17–19 Data from the multicentre that electroconvulsive therapy is typically admin- study by the Consortium for Research in Electro- istered 2 or 3 times per week during an acute course, achieving a clinically significant response Box 1: Evidence used in this review in 1–3 weeks with electroconvulsive therapy compares favourably with the 4–6 weeks typic al - We searched PubMed for articles about neuromodulation in major depression. We used the following search terms alone or in combination: ly required with antidepressant medications. “electroconvulsive therapy,” “transcranial magnetic stimulation,” “deep brain Routine use of general anesthesia, muscle stimulation,” “vagal nerve stimulation,” “direct current stimulation,” “major relaxants, continuous oxygenation, vital sign depression” and “treatment resistant depression;” we also searched using the monitoring and brief electrical stimuli have mini - acronyms “DBS,” “ECT” and “TMS.” We did not limit our searches by date. There were no meta-analyses of deep brain stimulation in depression, but we mized the risks associated with electroconvulsive found 21 meta-analyses on electroconvulsive therapy and 17 on transcranial therapy. The mortality rate has been estimated to magnetic stimulation. We found no published randomized controlled trials of be less than 1 death per 73 440 treatments.20 The deep brain stimulation for the treatment of depression. We identified most common adverse effects (myalgia [1 in 5 134 arti cles on transcranial magnetic stimulation for depression, as well as patients], headache [1 in 3 pa tients]) are transient, 230 arti cles on electroconvulsive therapy. All results were manually searched. We included only those that were relevant and enhanced our discussion and lasting minutes to hours, and can be treated with those with clearly defined patient populations and outcome measures. analgesics.21 Electroconvulsive therapy is associ- ated with immediate posttreatment disorientation B. Deep brain stimulation 24 32 25 14c A. Transcranial magnetic stimulation Glutamate C. Electroconvulsive therapy AMPAR NMDAR 2+ Ca 2 1 CaM CaMKII Figure 1: (A) Transcranial magnetic stimulation is thought to produce durable changes in synaptic strength via the NMDA-receptor– dependent mechanisms of long-term potentiation and long-term depression. Simultaneous stimulation of presynaptic and postsynap- tic neurons strengthens or weakens the synaptic connection, depending on the frequency and pattern of stimulation. When applied to areas of prefrontal cortex that are hypoactive in depression, repetitive transcranial magnetic stimulation gradually increases their activity, thereby relieving the illness. (B) With deep brain stimulation, electrodes are inserted under stereotactic guidance into regions of the brain believed to drive maladaptive thoughts and behaviours. Constant electricity, provided by an implanted pulse generator, disrupts neural activity both at local sites (i.e., at the target) and at remote, yet connected, structures, comprising a “mood circuit.” (C) Electroconvulsive therapy induces ictal activity, as shown by the electroencephalographic recording. 34 CMAJ, January 7, 2014, 186(1) Review and retrograde amnesia. Although these effects can produce long-lasting changes in neural are generally short lived, a 6-month longitudinal excitability. The frequency of stimulation deter- follow-up study found that retrograde amnesia mines the effects of transcranial magnetic stimula- persisted in about 1 in 8 patients (12.4%).22 The tion. Low-frequency (< 5 Hz) stimulation inhibits amnestic effects of electroconvulsive therapy are neuronal firing, and high-frequency (> 5 Hz) stim- greater for recent events (i.e., within 3 mo of first ulation increases neuronal firing rates.26 treatment) than for remote events (i.e., greater Transcranial magnetic stimulation typically than 3 yr).23 Factors associated with greater cog- involves 10–30 treatment sessions of 15–45 min- nitive impairment following electroconvulsive utes duration, administered once daily, 5 days a therapy include pre-existing cognitive impair- week on an outpatient basis. High-frequency ment, older age and the use of bilateral electro- stimulation to the dorsolateral prefrontal cortex convulsive therapy.24 There are no absolute con- is the typical protocol for patients with major traindications to electroconvulsive therapy, and it depressive disorder, based on neuroimaging evi- can be used safely
Load more

Recommended publications
  • Investigation of the Cardiac Effects of Pancuronium, Rocuronium, Vecuronium, and Mivacurium on the Isolated Rat Atrium
    Current Therapeutic Research VOLUME ,NUMBER ,OCTOBER Investigation of the Cardiac Effects of Pancuronium, Rocuronium, Vecuronium, and Mivacurium on the Isolated Rat Atrium Sinan Gursoy, MD1; Ihsan Bagcivan, MD2; Nedim Durmus, MD3; Kenan Kaygusuz, MD1; Iclal Ozdemir Kol, MD1; Cevdet Duger, MD1; Sahin Yildirim, MD2; and Caner Mimaroglu, MD1 1Department of Anesthesiology, Cumhuriyet University School of Medicine, Sivas, Turkey; 2Department of Pharmacology, Cumhuriyet University School of Medicine, Sivas, Turkey; and 3Ministry of Health of Turkey, General Directorate of Pharmacy and Pharmaceuticals, Ankara, Turkey ABSTRACT Background: Pancuronium, vecuronium, rocuronium, and mivacurium are nondepolarizing neuromuscular blocking agents that affect the cardiovascular system with different potencies. Their cardiovascular effects are clinically significant in the anesthetic management of patients, particularly those undergoing cardiac surgery. Objective: We aimed to compare the cardiac effects of these compounds, such as heart rate and developed force, in one species under identical experimental conditions in isolated rat atria. Methods: The left or right atria of rats were removed and suspended in organ baths. Pancuronium, vecuronium, rocuronium, or mivacurium were added cumula- tively (10–9–10–5 M) in the presence and absence of the nonselective ␤-blocker propranolol (10–8 M) and the noradrenaline reuptake inhibitor desipramine (10–7 M), and heart rate changes were recorded in spontaneously beating right atria. Left atrial preparations were stimulated by electrical field stimulation using a bipolar platinum electrode, and the effects of cumulative concentrations of these nondepolarizing neuromuscular blocking agents on the developed force in the presence and absence of propranolol (10–8 M) and desipramine (10–7 M) were recorded. Results: Pancuronium increased heart rate in a dose-dependent manner com- pared with the control group (P Ͻ 0.027).
    [Show full text]
  • Additional Antidepressant Pharmacotherapies According to A
    orders & is T D h e n r Werner and Coveñas, Brain Disord Ther 2016, 5:1 i a a p r y B Brain Disorders & Therapy DOI: 10.4172/2168-975X.1000203 ISSN: 2168-975X Review Article Open Access Additional Antidepressant Pharmacotherapies According to a Neural Network Felix-Martin Werner1, 2* and Rafael Coveñas2 1Higher Vocational School of Elderly Care and Occupational Therapy, Euro Academy, Pößneck, Germany 2Laboratory of Neuroanatomy of the Peptidergic Systems, Institute of Neurosciences of Castilla y León (INCYL), University of Salamanca, Salamanca, Spain Abstract Major depression, a frequent psychiatric disease, is associated with neurotransmitter alterations in the midbrain, hypothalamus and hippocampus. Deficiency of postsynaptic excitatory neurotransmitters such as dopamine, noradrenaline and serotonin and a surplus of presynaptic inhibitory neurotransmitters such as GABA and glutamate (mainly a postsynaptic excitatory and partly a presynaptic inhibitory neurotransmitter), can be found in the involved brain regions. However, neuropeptide alterations (galanin, neuropeptide Y, substance P) also play an important role in its pathogenesis. A neural network is described, including the alterations of neuroactive substances at specific subreceptors. Currently, major depression is treated with monoamine reuptake inhibitors. An additional therapeutic option could be the administration of antagonists of presynaptic inhibitory neurotransmitters or the administration of agonists/antagonists of neuropeptides. Keywords: Acetylcholine; Bupropion; Dopamine; GABA; Galanin; in major depression and to point out the coherence between single Glutamate; Hippocampus; Hhypothalamus; Major depression; neuroactive substances and their corresponding subreceptors. A Midbrain; Neural network; Neuropeptide Y; Noradrenaline; Serotonin; question should be answered, whether a multimodal pharmacotherapy Substance P with an agonistic or antagonistic effect at several subreceptors is higher than the current conventional antidepressant treatment.
    [Show full text]
  • Current P SYCHIATRY
    Current p SYCHIATRY N ew Investigators Tips to manage and prevent discontinuation syndromes Informed tapering can protect patients when you stop a medication Sriram Ramaswamy, MD Shruti Malik, MBBS, MHSA Vijay Dewan, MD Instructor, department of psychiatry Foreign medical graduate Assistant professor Creighton University Department of psychiatry Omaha, NE University of Nebraska Medical Center Omaha, NE bruptly stopping common psychotropics New insights on psychotropic A —particularly antidepressants, benzodi- drug safety and side effects azepines, or atypical antipsychotics—can trigger a discontinuation syndrome, with: This paper was among those entered in the 2005 • rebound or relapse of original symptoms Promising New Investigators competition sponsored • uncomfortable new physical and psycho- by the Neuroleptic Malignant Syndrome Information Service (NMSIS). The theme of this year’s competition logical symptoms was “New insights on psychotropic drug safety and • physiologic withdrawal at times. side effects.” To increase health professionals’ awareness of URRENT SYCHIATRY 1 C P is honored to publish this peer- the risk of these adverse effects, this article reviewed, evidence-based article on a clinically describes discontinuation syndromes associated important topic for practicing psychiatrists. with various psychotropics and offers strategies to NMSIS is dedicated to reducing morbidity and anticipate, recognize, and manage them. mortality of NMS by improving medical and psychiatric care of patients with heat-related disorders; providing
    [Show full text]
  • PRESCRIBED DRUGS and NEUROLOGICAL COMPLICATIONS K a Grosset, D G Grosset Iii2
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.2004.045757 on 16 August 2004. Downloaded from PRESCRIBED DRUGS AND NEUROLOGICAL COMPLICATIONS K A Grosset, D G Grosset iii2 J Neurol Neurosurg Psychiatry 2004;75(Suppl III):iii2–iii8. doi: 10.1136/jnnp.2004.045757 treatment history is a fundamental part of the healthcare consultation. Current drugs (prescribed, over the counter, herbal remedies, drugs of misuse) and how they are taken A(frequency, timing, missed and extra doses), drugs tried previously and reason for discontinuation, treatment response, adverse effects, allergies, and intolerances should be taken into account. Recent immunisations may also be of importance. This article examines the particular relevance of medication in patients presenting with neurological symptoms. Drugs and their interactions may contribute in part or fully to the neurological syndrome, and treatment response may assist diagnostically or in future management plans. Knowledge of medicine taking behaviour may clarify clinical presentations such as analgesic overuse causing chronic daily headache, or severe dyskinesia resulting from obsessive use of dopamine replacement treatment. In most cases, iatrogenic symptoms are best managed by withdrawal of the offending drug. Indirect mechanisms whereby drugs could cause neurological problems are beyond the scope of the current article—for example, drugs which raise blood pressure or which worsen glycaemic control and consequently increase the risk of cerebrovascular disease, or immunosupressants
    [Show full text]
  • Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys
    1521-0103/366/2/397–409$35.00 https://doi.org/10.1124/jpet.118.248070 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:397–409, August 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys Sarah L. Withey,1 Michelle R. Doyle,1,2 Jack Bergman, and Rajeev I. Desai Preclinical Pharmacology Laboratory, McLean Hospital/Harvard Medical School, Belmont, Massachusetts Received January 27, 2018; accepted May 17, 2018 ABSTRACT Evidence suggests that the a4b2, but not the a7, subtype of the except for lobeline, the nicotinic agonists produced either full nicotinic acetylcholine receptor (nAChR) plays a key role in [(1)-epibatidine, (2)-epibatidine, and nicotine] or partial (vare- Downloaded from mediating the behavioral effects of nicotine and related drugs. nicline, cytisine, anabaseine, and isoarecolone) substitution for However, the importance of other nAChR subtypes remains (1)-epibatidine. In interaction studies with antagonists differing unclear. The present studies were conducted to examine the in selectivity, (1)-epibatidine discrimination was substan- involvement of nAChR subtypes by determining the effects of tively antagonized by mecamylamine, slightly attenuated selected nicotinic agonists and antagonists in squirrel monkeys by hexamethonium (peripherally restricted) or dihydro- b a either 1) responding for food reinforcement or 2) discriminating the -erythroidine, and not altered by methyllycaconitine ( 7 jpet.aspetjournals.org nicotinic agonist (1)-epibatidine (0.001 mg/kg) from vehicle. In selective). Varenicline and cytisine enhanced (1)-epibati- food-reinforcement studies, nicotine, (1)-epibatidine, varenicline dine’s discriminative-stimulus effects.
    [Show full text]
  • Channelopathies Influence on Neurotransmitters Monitorable By
    Medical and Clinical Archives Review Article ISSN: 2515-1053 Channelopathies influence on neurotransmitters monitorable by real time in situ voltammetry, a review and research proposal Francesco Crespi* Biology Department, GSK, Verona, Italy Introduction Ataxia Channels are pores and through them ions flow across the cell Ataxia is a non-specific clinical condition characterized by membrane and depolarize or hyperpolarize the cell. They open in dysfunction of the areas of the nervous system that control movement, response to voltage changes or binding of a chemical messenger, such as the cerebellum [10]. such as a neurotransmitter (i.e. ligand-gated ion channels). A possible link between cerebellar ataxia and the metabolism Biochemically, channels are specialized membrane macro-molecular of serotonin has been proposed as anti-ataxic effect of buspirone protein complexes divided into distinct protein units called sub-units. hydrochloride, a serotoninergic 5-hydroxytryptamine1A (5-HT1A) Each sub-unit has a specific function and is encoded by a different gene. agonist, in a homogenous group of patients characterized by the These proteins play heterogeneous physiological roles such as impulse same well-defined single condition i.e. cerebellary cortical atrophy generation and propagation, synaptic transmission and plasticity, has been reported [11]. Accordingly, it has been observed that hormonal secretion, hearth rhythm, blood pressure regulation, salt- 5-hydroxytryptophan, serotonin precursor, is more effective than water balance, cell proliferation and survival. Thus, defects in ion placebo improving neurological symptoms in patients with Friedreich channels function may cause diverse and severe diseases collectively ataxia (FA) [12]. FA is an autosomal recessive genetic illness responsible known as channelization [1,2].
    [Show full text]
  • Neurotransmission Product Guide | Edition 1
    Neurotransmission Product Guide | Edition 1 Delphinium Delphinium A source of Methyllycaconitine Contents by Research Area: • Dopaminergic Transmission • Glutamatergic Transmission • Opioid Peptide Transmission • Serotonergic Transmission • Chemogenetics Tocris Product Guide Series Neurotransmission Research Contents Page Principles of Neurotransmission 3 Dopaminergic Transmission 5 Glutamatergic Transmission 6 Opioid Peptide Transmission 8 Serotonergic Transmission 10 Chemogenetics in Neurotransmission Research 12 Depression 14 Addiction 18 Epilepsy 20 List of Acronyms 22 Neurotransmission Research Products 23 Featured Publications and Further Reading 34 Introduction Neurotransmission, or synaptic transmission, refers to the passage of signals from one neuron to another, allowing the spread of information via the propagation of action potentials. This process is the basis of communication between neurons within, and between, the peripheral and central nervous systems, and is vital for memory and cognition, muscle contraction and co-ordination of organ function. The following guide outlines the principles of dopaminergic, opioid, glutamatergic and serotonergic transmission, as well as providing a brief outline of how neurotransmission can be investigated in a range of neurological disorders. Included in this guide are key products for the study of neurotransmission, targeting different neurotransmitter systems. The use of small molecules to interrogate neuronal circuits has led to a better understanding of the under- lying mechanisms of disease states associated with neurotransmission, and has highlighted new avenues for treat- ment. Tocris provides an innovative range of high performance life science reagents for use in neurotransmission research, equipping researchers with the latest tools to investigate neuronal network signaling in health and disease. A selection of relevant products can be found on pages 23-33.
    [Show full text]
  • Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gutlbrain Interaction): a Rome Foundation Working Team Report Douglas A
    Gastroenterology 2018;154:1140–1171 SPECIAL REPORT Neuromodulators for Functional Gastrointestinal Disorders (Disorders of GutLBrain Interaction): A Rome Foundation Working Team Report Douglas A. Drossman,1,2 Jan Tack,3 Alexander C. Ford,4,5 Eva Szigethy,6 Hans Törnblom,7 and Lukas Van Oudenhove8 1Center for Functional Gastrointestinal and Motility Disorders, University of North Carolina, Chapel Hill, North Carolina; 2Center for Education and Practice of Biopsychosocial Care and Drossman Gastroenterology, Chapel Hill, North Carolina; 3Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium; 4Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom; 5Leeds Gastroenterology Institute, St James’s University Hospital, Leeds, United Kingdom; 6Departments of Psychiatry and Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; 7Departments of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and 8Laboratory for BrainÀGut Axis Studies, Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium BACKGROUND & AIMS: Central neuromodulators (antide- summary information and guidelines for the use of central pressants, antipsychotics, and other central nervous neuromodulators in the treatment of chronic gastrointestinal systemÀtargeted medications) are increasingly used for treat- symptoms and FGIDs. Further studies are needed to confirm ment
    [Show full text]
  • Cannabis Use in Fibromyalgia M
    CHAPTER e16 Cannabis Use in Fibromyalgia M. Farré * , A. Farré ** , J. Fiz † , M. Torrens ‡ * Clinical Pharmacology Unit, Germans Trias i Pujol University Hospital—IGTP, and Human Pharmacology Unit, Hospital del Mar Medical Research Institute—IMIM, and Autonomous University of Barcelona, Barcelona, Spain ** Dual Disorder Unit, Addiction Program, Institute of Neuropsychiatry and Addiction—INAD, and Hospital del Mar Medical Research Institute—IMIM, Barcelona, Spain † CEDIR, Center for Diagnosis and Rehabilitation, San Martín Santa Fe, Argentina ‡ Addiction Program, Institute of Neuropsychiatry and Addiction—INAD, and Hospital del Mar Medical Research Institute—IMIM, Barcelona, Spain SUMMARY POINTS KEY FACTS OF FIBROMYALGIA • This chapter focuses on the cannabis and • Fibromyalgia is a chronic disorder characterized by fi bromyalgia and begins with the diagnosis and widespread pain and tenderness, often accompanied treatment of this condition. by fatigue, memory problems, and sleep disturbances. • Therapy includes nonpharmacological and • The origin of fi bromyalgia is unknown but it seems pharmacological treatments. to be related to a sensitization of the central nervous system. • Some drugs have demonstrated effi cacy in • The diagnosis of fi bromyalgia is based on clinical randomized controlled trials (pregabalin, symptoms, and routine laboratory and diagnostic tests duloxetine, milnacipran, amitriptyline, serotonin are normal. selective reuptake inhibitors, and cyclobenzaprine). • There is no specifi c treatment for fi bromyalgia. • Cannabis products are frequently used in patients Nonpharmacological and pharmacological therapies with fi bromyalgia. Different surveys showed that could help patients. most of the patients who tried medical marijuana • Some drugs are often used in the treatment of found it to be effective or very effective for the fi bromyalgia pain.
    [Show full text]
  • Using Fluoxetine As a Model
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by OAR@UM Review Journal of Pharmacy And Pharmacology Understanding the molecular pharmacology of the serotonergic system: using fluoxetine as a model Lino Sghendo and Janet Mifsud Department of Clinical Pharmacology and Therapeutics, University of Malta, Msida, Malta Keywords Abstract molecular and clinical pharmacology; molecular and receptor pharmacology; Objectives Serotonin is a monoamine neurotransmitter that is widely distributed pharmacokinetics and drug disposition in the body and plays an important role in a variety of psychological and other body functions such as mood, sexual desire and function, appetite, sleep, memory and Correspondence learning, temperature regulation and social behaviour. This review will assess the Janet Mifsud, Department of Clinical use of fluoxetine, one of the most commonly used selective serotonin reuptake Pharmacology and Therapeutics, University of Malta, Msida, MDS2040, Malta. inhibitors, as a model for understanding the molecular pharmacology of the sero- E-mail: [email protected] toninergic system. Key findings Seven serotonin receptor families have been discovered to date. All Received June 21, 2011 serotonin receptors, except 5-HT3, are G-protein coupled, seven transmembrane Accepted September 22, 2011 receptors that activate an intracellular second messenger cascade. The 5-HT3 recep- tor is a ligand-gated ion channel. Furthermore, 5-HT1A receptors are known as doi: 10.1111/j.2042-7158.2011.01384.x autoreceptors since their stimulation inhibits the release serotonin in nerve termi- nals.A transporter protein found in the plasma membrane of serotonergic neurones is responsible for the reuptake of this neurotransmitter.
    [Show full text]
  • 'Party Drug' Turned Antidepressant Approaches Approval
    NEWS & ANALYSIS Nature Reviews Drug Discovery | Published online 30 Oct 2018; doi:10.1038/nrd.2018.187 ‘Party drug’ turned anti depressant approaches approval Johnson & Johnson has submitted its esketamine for regulatory approval, but researchers still don’t understand how the fast-acting antidepressant lifts moods. DrAfter123/DigitalVision Vectors Sara Reardon Monteggia, a neuroscientist at Vanderbilt later learned that the antibiotic, at low doses, University. blocks the NMDA receptor, a glutamate When researchers showed in 2006 that the Yet it is far from clear how this work will receptor. Then in the late 1990s,Nature when Reviews | Drug Discovery anaesthetic ketamine — also known as the play out. Whereas early evidence suggested psychiatrist John Krystal of Yale University club drug Special K — was a rapid and potent that ketamine acted through the NMDA was curious about whether the antidepressant, big pharmaceutical receptor, many of the first-generation neurotransmitter glutamate contributed to companies quickly jumped into the game. ketamine mimetics that were designed to act schizophrenia, he decided to test the known Extensive efforts to improve on decades-old on this target failed in clinical trials (TABLE 1). NMDA receptor antagonist ketamine in nine antidepressants had floundered, but ketamine Accumulating evidence now suggests that depressed patients. finally promised a novel mechanism of action ketamine’s antidepressant activity may be At the time, glutamate had mostly been and the potential to help treatment-resistant more complicated. studied for its role in learning and memory. But patients. As a result, some companies are quietly Krystal’s group found that ketamine induced a Because ketamine is an old drug and going back to the drawing board.
    [Show full text]
  • Is the Antidepressant Activity of Selective Serotonin Reuptake Inhibitors Mediated by Nicotinic Acetylcholine Receptors?
    molecules Review Is the Antidepressant Activity of Selective Serotonin Reuptake Inhibitors Mediated by Nicotinic Acetylcholine Receptors? Hugo R. Arias 1,*,†, Katarzyna M. Targowska-Duda 2,†, Jesús García-Colunga 3,† and Marcelo O. Ortells 4 1 Department of Pharmacology and Physiology, Oklahoma State University College of Osteopathic Medicine, Tahlequah, OK 74464, USA 2 Department of Biopharmacy, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 3 Departamento de Neurobiología Celular y Molecular, Instituto de Neurobiología, Campus Juriquilla, Universidad Nacional Autónoma de México, Querétaro 76230, Mexico; [email protected] 4 Facultad de Medicina, Universidad de Morón, CONICET, Morón 1708, Argentina; [email protected] * Correspondence: [email protected]; Tel.: +1-918-525-6324; Fax: +1-918-280-2515 † These authors contributed equally to this work. Abstract: It is generally assumed that selective serotonin reuptake inhibitors (SSRIs) induce an- tidepressant activity by inhibiting serotonin (5-HT) reuptake transporters, thus elevating synaptic 5-HT levels and, finally, ameliorates depression symptoms. New evidence indicates that SSRIs may also modulate other neurotransmitter systems by inhibiting neuronal nicotinic acetylcholine receptors (nAChRs), which are recognized as important in mood regulation. There is a clear and strong association between major depression and smoking, where depressed patients smoke twice as much as the normal population. However, SSRIs are not efficient for smoking cessation therapy. In patients with major depressive disorder, there is a lower availability of functional nAChRs, although Citation: Arias, H.R.; their amount is not altered, which is possibly caused by higher endogenous ACh levels, which Targowska-Duda, K.M.; consequently induce nAChR desensitization. Other neurotransmitter systems have also emerged García-Colunga, J.; Ortells, M.O.
    [Show full text]